Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine.
Infants born to human immunodeficiency virus type 1 (HIV-1)-infected mothers were immunized at birth and at ages 4, 12, and 20 weeks with low-, medium-, or high-dose recombinant gp120 vaccine with MF59 adjuvant (HIV-1(SF-2); n=52) or with MF59 alone as a placebo (n=9). An accelerated schedule (birth and ages 2, 8, and 20 weeks) was used for an additional 10 infants receiving the defined optimal dose and for 3 infants receiving placebo. At 24 weeks, anti-gp120 ELISA titers were greater for vaccine-immunized than for placebo-immunized infants on both schedules, and 87% of vaccinees had a vaccine-induced antibody response. At 12 weeks, antibody titers of infants on the accelerated vaccine schedule exceeded those of infants receiving placebo (4949 vs. 551; P=.01), and 63% of the vaccinees met the response criteria. Thus, an accelerated schedule of gp120 vaccinations generated an antibody response to HIV-1 envelope distinct from transplacental maternal antibody by age 12 weeks. These results provide support for further studies of vaccine strategies to prevent mother-to-infant HIV-1 transmission.
McFarland
E J
EJ
Department of Pediatrics, University of Colorado Health Science Center, Denver, CO 80262, USA. Betsy.mcfarland@uchsc.edu
Borkowsky
W
W
Fenton
T
T
Wara
D
D
McNamara
J
J
Samson
P
P
Kang
M
M
Mofenson
L
L
Cunningham
C
C
Duliege
A M
AM
Sinangil
F
F
Spector
S A
SA
Jimenez
E
E
Bryson
Y
Y
Burchett
S
S
Frenkel
L M
LM
Yogev
R
R
Gigliotti
F
F
Luzuriaga
K
K
Livingston
R A
RA
D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D000914:Antibodies, Viral / Q000097:blood*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D015699:HIV Envelope Protein gp120 / Q000008:administration & dosage* / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011136:Polysorbates; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology; D013185:Squalene / Q000276:immunology; D014611:Vaccination; D022223:Vaccines, Subunit / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
D016915:AIDS Vaccines; D000914:Antibodies, Viral; D015699:HIV Envelope Protein gp120; C089950:MF59 oil emulsion; D011136:Polysorbates; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D013185:Squalene